Modality
Cell Therapy
MOA
DLL3 ADC
Target
PSMA
Pathway
Cell Cycle
WMCLL
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Nov 2031
ApprovedCurrent
NCT06785436
1,262 pts·CLL
2024-05→TBD·Active
NCT05766446
221 pts·WM
2019-01→2026-08·Recruiting
NCT07821273
886 pts·WM
2019-07→2031-11·Recruiting
+1 more trial
5,297 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-08-205mo awayPh3 Readout· WM
2028-09-222.5y awayPh3 Readout· CLL
2031-11-115.6y awayPh3 Readout· WM
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Active
Approved
Recruit…
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2026-08-20 · 5mo away
WM
Ph3 Readout
2028-09-22 · 2.5y away
CLL
Ph3 Readout
2031-11-11 · 5.6y away
WM
RecruitingActive|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06785436 | Approved | CLL | Active | 1262 | VA |
| NCT05766446 | Approved | WM | Recruiting | 221 | Safety |
| NCT07821273 | Approved | WM | Recruiting | 886 | PASI75 |
| NCT08514369 | Approved | CLL | Active | 2928 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| DAW-8159 | Day One Bio | Phase 2 | PSMA |